Disclosure MEL has reported consulting or advisory role for Debiopharm, Galderma, Johnson & Johnson, Novocure, Merck Sharp & Dohme, Janssen, Menlo, Novartis, F. Hoffmann-La Roche AG, AbbVie Inc., Amgen, E.R. Squibb & Sons, LLC, EMD Serono, AstraZeneca, Genentech, Loxo, Oncoderm, Seattle Genetics, Bayer, Lutris, Paxman Coolers, onQuality, Novartis, Wiley, Azitra, ADC Therapeutics, QED, Lutris, NCODA, Apricity and Takeda Millennium, he has received research funding from Berg, Veloce, US Biotest, Lutris, Johnson & Johnson, research support from AstraZeneca and Novartis and grants from NIH/NCI Cancer Center and NIH/NIAMS; VS has reported advisory board and/or honoraria for presentations for Bristol-Myers Squibb, Novartis, Pierre Fabre, Bayer, Incyte and Roche; PAG has reported research funding, advisory board and/or honoraria for presentations for Bayer, Beiersdorf, Galderma and Novartis; CvdH has reported research funding from Dignitana AB and Paxman Ltd and travel expenses from Paxman Ltd; PF-P has reported advisory role for Janssen, Roche, AbbVie, Merck Sharp & Dohme, Sun Pharmaceuticals, Merck, Novartis, Sanofi, Leo and Lilly, and he has conducted clinical trials for Arena, Akaal Pharma, XOMA, Kyowa Hakko Kirin, AbbVie, OncoSec, Lilly, CSL Behring, Boehringer Ingelheim, Pfizer, mRage, Eisai, Jiangsu Hengrui, Bristol-Myers Squibb, Sun Pharma, Novartis, Roche, Galderma, Regeneron, UCB, GlaxoSmithKline and Amgen; DS has reported advisory role for Janssen, Roche, Novartis, Pfizer, Lilly, Sanofi, Merck, Bristol-Myers Squibb, Merck Sharpe & Dohme, AstraZeneca and Boehringer; FJ has reported advisory role for Tesaro, has received honoraria and travel expenses from Tesaro, Merck Sharp & Dohme, Riemser and Amgen; KJ has reported advisory board and/or honoraria for presentations for Merck Sharp & Dohme, Merck, Amgen, Hexal, RIEMSER, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, POMME-med, PharmaMar, prIME Oncology and Onko Update.